Cardiovascular Manifestations of Patients with Long COVID.

Publication date: Jul 13, 2025

Background: This study investigates the potential mechanisms behind changes in cardiac structure and function in long COVID patients. Methods: This study involved 176 consecutive outpatients in follow-up care (average age 55. 9 years; 58. 5% male) who experienced symptoms for over 12 weeks (average 6. 2 +/- 2. 7 months), following coronavirus infection (COVID-19). Results: The patients with long COVID and cardiovascular manifestations were significantly more hospitalized (88. 5% vs. 75. 9%) and had longer hospital stays. Significant echocardiography changes were observed in the left ventricular ejection fraction (LVEF) (59. 6 +/- 5. 4% vs. 62. 5 +/- 3. 8%); longitudinal strain (LS) in the sub-endocardium and intra-myocardium layers (-20. 9 vs. -22. 0% and -18. 6 vs. -19. 5%); circumferential strain (CS) in the sub-epicardium layers (-9. 6 vs. -10. 5%); and CS post-systolic shortening (CS PSS) (0. 138 vs. 0. 088 s). Additionally, pathological cardiac magnetic resonance (CMR) findings were seen in 58. 2% of the group of patients with long COVID and cardiovascular manifestation; 43. 3% exhibited positive late gadolinium enhancement (LGE), 21. 0% had elevated native T1 mapping, and 22. 4% had elevated native T2 mapping. Conclusions: Most patients with long COVID showed structural and functional changes in their cardiovascular systems, primarily caused by prolonged inflammation. Using multimodality imaging is important for uncovering the mechanisms to predict chronic myocarditis, early-stage heart failure, and pre-ischemic states, which can lead to serious complications. Recognizing the specific cardiovascular phenotypes associated with long COVID is essential in order to provide timely and appropriate treatment.

Open Access PDF

Concepts Keywords
Basel cardiovascular diseases
Coronavirus COVID-19
Echocardiography echocardiography
Long long COVID
Outpatients multimodality imaging

Semantics

Type Source Name
disease MESH Long COVID
disease MESH coronavirus infection
disease MESH COVID-19
drug DRUGBANK Gadolinium
disease MESH inflammation
disease MESH myocarditis
disease MESH heart failure
disease MESH complications
drug DRUGBANK Coenzyme M
disease MESH cardiovascular diseases
disease MESH infection
disease MESH chest pain
disease MESH syncope
disease MESH autoimmune responses
disease MESH thrombosis
disease IDO production
disease MESH dysbiosis
disease MESH viral infections
drug DRUGBANK Isoxaflutole
disease MESH dissociation
disease MESH morbidity
disease MESH fibrosis
drug DRUGBANK Methionine
disease MESH abnormalities
disease MESH contraindications
disease MESH cerebral aneurysm
disease MESH aids
disease MESH claustrophobia
disease IDO history

Original Article

(Visited 2 times, 1 visits today)